SunTrust Banks, Inc. set a $136.00 price target on Zimmer Biomet Holdings Inc (NYSE:ZBH) in a research note released on Wednesday. The firm currently has a buy rating on the medical equipment provider’s stock.
ZBH has been the subject of several other reports. Stifel Nicolaus reiterated a hold rating and issued a $125.00 price objective on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Gabelli began coverage on Zimmer Biomet Holdings in a research report on Thursday, August 24th. They issued a buy rating and a $142.00 price objective for the company. Zacks Investment Research lowered Zimmer Biomet Holdings from a hold rating to a strong sell rating in a research report on Tuesday, August 8th. BMO Capital Markets reiterated a buy rating and issued a $136.00 price objective on shares of Zimmer Biomet Holdings in a research report on Tuesday, July 11th. Finally, Wells Fargo & Company reiterated a market weight rating on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $134.75.
Shares of Zimmer Biomet Holdings (NYSE ZBH) opened at $109.25 on Wednesday. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.80 and a current ratio of 1.47. The company has a market cap of $22.09 billion, a P/E ratio of 13.92, a PEG ratio of 1.53 and a beta of 1.17. Zimmer Biomet Holdings has a 1 year low of $95.63 and a 1 year high of $133.49.
Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). The company had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.83 billion. Zimmer Biomet Holdings had a net margin of 8.36% and a return on equity of 16.29%. Zimmer Biomet Holdings’s revenue for the quarter was down .8% on a year-over-year basis. During the same quarter last year, the company earned $1.79 earnings per share. research analysts expect that Zimmer Biomet Holdings will post 8.03 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, October 27th. Investors of record on Friday, September 22nd were issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date of this dividend was Thursday, September 21st. Zimmer Biomet Holdings’s dividend payout ratio is currently 29.91%.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZBH. Bronfman E.L. Rothschild L.P. lifted its position in Zimmer Biomet Holdings by 25.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after purchasing an additional 167 shares during the period. Parkside Financial Bank & Trust lifted its position in Zimmer Biomet Holdings by 3.9% in the second quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock valued at $112,000 after purchasing an additional 33 shares during the period. Parallel Advisors LLC lifted its position in Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after purchasing an additional 199 shares during the period. IHT Wealth Management LLC lifted its position in Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after purchasing an additional 256 shares during the period. Finally, BB&T Investment Services Inc. acquired a new stake in Zimmer Biomet Holdings in the second quarter valued at about $144,000. 85.26% of the stock is currently owned by hedge funds and other institutional investors.
Zimmer Biomet Holdings Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
What are top analysts saying about Zimmer Biomet Holdings Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zimmer Biomet Holdings Inc and related companies.